Fjarde AP Fonden Fourth Swedish National Pension Fund Raises Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in Moderna, Inc. (NASDAQ:MRNA) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,730 shares of the company’s stock after purchasing an additional 3,300 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Moderna were worth $2,484,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Knuff & Co LLC grew its stake in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares during the period. Stephens Inc. AR grew its stake in Moderna by 7.9% in the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after purchasing an additional 245 shares during the period. Allworth Financial LP grew its stake in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares during the period. Howard Capital Management Inc. grew its stake in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares during the period. Finally, Larson Financial Group LLC grew its stake in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Performance

MRNA stock opened at $33.58 on Thursday. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The business’s 50-day moving average is $37.74 and its two-hundred day moving average is $51.74. The company has a market cap of $12.92 billion, a price-to-earnings ratio of -3.62 and a beta of 1.59.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is owned by company insiders.

Analyst Ratings Changes

MRNA has been the topic of a number of recent research reports. Evercore ISI set a $50.00 target price on Moderna in a research note on Friday, February 14th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a research note on Friday, February 14th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Piper Sandler reissued an “overweight” rating and issued a $69.00 target price (down from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and cut their target price for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $60.63.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.